Clinical trial results for
previously treated
classical Hodgkin
lymphoma
For adults with previously treated classical Hodgkin lymphoma including an autologous stem cell transplant whose cancer has come back or spread
Actor portrayals.
An FDA-approved immunotherapy that could make tumors either shrink or disappear completely
About the clinical trial
In the two different clinical trials, the overall response rate and duration of response to OPDIVO were looked at in 258 people with classical Hodgkin lymphoma (cHL) that had come back or spread after an autologous stem cell transplant. Most of these people had also been treated with Adcetris® (brentuximab vedotin).
People saw their tumors shrink or disappear completely with OPDIVO
OPDIVO
Tumors disappeared completely (complete response)
Tumors shrank
(partial response)
Tumors shrank or disappeared completely (overall response)
Of the people who responded to OPDIVO, the shortest response lasted less than one month, and the longest response lasted 23.1 months. With a median follow-up time of 6.7 months, more than half of the people who responded were still responding in the clinical trials.
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
Duration of response is the measure of how long these responses lasted.
OPDIVO will not work for everyone. Individual results may vary.
About the smaller group also studied
Of the 258 people included in the two clinical trials, a smaller group of 95 people that had an autologous stem cell transplant and had also been treated with Adcetris® (brentuximab vedotin) was studied.
People saw their tumors shrink or disappear completely with OPDIVO
OPDIVO
Tumors disappeared completely (complete response)
Tumors shrank
(partial response)
Tumors shrank or disappeared completely (overall response)
Of the 63 people who responded to OPDIVO, half had a response for at least 13.1 months, also known as the median duration of response. The range for all people who responded was between zero and 23.1 months.
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
Duration of response is the measure of how long these responses lasted. The median duration of response is the length of time half of the patients were still responding to treatment.
OPDIVO will not work for everyone. Individual results may vary.
Getting an infusion
See your recommended treatment plan and what to expect from an infusion
For adults with previously treated classical Hodgkin lymphoma including an autologous stem cell transplant whose cancer has come back or spread
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the medicine brentuximab vedotin before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.